Company intelligence / Profile preview
Genervon Biopharmaceuticals
Pasadena, California, United Statesgenervon.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 2
01
Overview
Completed Phase 2A randomized double-blind trials for ALS at Massachusetts General and Columbia Presbyterian. GM6 has shown to modulate key biomarkers associated with neurodegenerative disorders and improve clinical outcomes. The company has obtained orphan-drug designation and fast-track designation for GM6 to treat ALS.
- Therapeutic areas
- Neurology
- Modalities
- Peptides
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Genervon Biopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genervon Biopharmaceuticals.